Access cutting-edge kidney cancer treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access kidney cancer specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related kidney cancer treatment provided free
The purpose of this study is to see if the combination of 177Lu-girentuximab and nivolumab is a safe and effective treatment for advanced clear cell renal cell carcinoma/ccRCC that has the CAIX protein.
Sponsor: Memorial Sloan Kettering Cancer Center
Check if you qualify for this kidney cancer clinical trial in New York, NY
If you're searching for kidney cancer treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced kidney cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.